| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 11.0899 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 11.0899. The average price that 2413.T shares were previous bought at was JPY 13.9573. The current market price is -20.5% lower than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 29,483 compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 15.3167 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 15.3167. The average price that 4151.T shares were previous bought at was JPY 16.0268. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 35,514 compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 35.1726 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 35.1726. The average price that 4502.T shares were previous bought at was JPY 29.6131. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 34,988 compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 15.5621 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 15.5621. The average price that 4503.T shares were previous bought at was JPY 11.9155. The current market price is 30.6% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 1,065,122 compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 21.6314 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 21.6314. The average price that 4507.T shares were previous bought at was JPY 17.4515. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 18,268 compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 54.8787 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 54.8787. The average price that 4519.T shares were previous bought at was JPY 49.3536. The current market price is 11.2% higher than average price they were purchased at. The value of the holding in 4519.T has fallen by JPY 159,734 compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 28.5742 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 28.5742. The average price that 4523.T shares were previous bought at was JPY 30.1288. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 43,963 compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 13.0375 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 13.0375. The average price that 4543.T shares were previous bought at was JPY 15.6274. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in 4543.T has fallen by JPY 4,003 compared to the previous valuation of Terumo Corporation |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 18.2908 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 18.2908. The average price that 4568.T shares were previous bought at was JPY 23.0746. The current market price is -20.7% lower than average price they were purchased at. The value of the holding in 4568.T has fallen by JPY 124,920 compared to the previous valuation of Daiichi Sankyo Company, Limited |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 59.5709 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 59.5709. The average price that 4578.T shares were previous bought at was JPY 55.517. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 3,060 compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.52791 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.52791. The average price that 6869.T shares were previous bought at was JPY 11.1967. The current market price is -14.9% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 29,799 compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.0207 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.0207. The average price that 7733.T shares were previous bought at was JPY 12.7281. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 1,410 compared to the previous valuation of Olympus Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 168.595 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 168.595. The average price that 7741.T shares were previous bought at was JPY 147.114. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 35,997 compared to the previous valuation of HOYA Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 129.58 | USD 0 | The current share valuation price of A based on adjusted close was USD 129.58. The average price that A shares were previous bought at was USD 136.647. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in A has fallen by USD 378,882 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 223.43 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 223.43. The average price that ABBV shares were previous bought at was USD 211.499. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 380,945 compared to the previous valuation of AbbVie Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 110.83 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 110.83. The average price that ABT shares were previous bought at was USD 130.105. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 147,124 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 78.3489 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 78.3489. The average price that ALC.SW shares were previous bought at was CHF 78.6947. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in ALC.SW has fallen by CHF 133,660 compared to the previous valuation of |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 328.16 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 328.16. The average price that ALNY shares were previous bought at was USD 415.922. The current market price is -21.1% lower than average price they were purchased at. The value of the holding in ALNY has fallen by USD 136,623 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 384.32 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 384.32. The average price that AMGN shares were previous bought at was USD 307.773. The current market price is 24.9% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 1,708,921 compared to the previous valuation of Amgen Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 822.164 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 822.164. The average price that ARGX.BR shares were previous bought at was EUR 846.415. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in ARGX.BR has fallen by EUR 104,540 compared to the previous valuation of Argenx SE |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 192.012 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 192.012. The average price that AZN.L shares were previous bought at was GBP 169.979. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 116,109 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 21.73 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 21.73. The average price that BAX shares were previous bought at was USD 19.5094. The current market price is 11.4% higher than average price they were purchased at. The value of the holding in BAX has increased by USD 34,550 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 54.1333 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 54.1333. The average price that BAYN.DE shares were previous bought at was EUR 37.3213. The current market price is 45.0% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 25,151 compared to the previous valuation of Bayer AG however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 210.02 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 210.02. The average price that BDX shares were previous bought at was USD 189.573. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in BDX has increased by USD 57,038 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 201.18 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 201.18. The average price that BIIB shares were previous bought at was USD 174.144. The current market price is 15.5% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 236,893 compared to the previous valuation of Biogen Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 112.049 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 112.049. The average price that BIM.PA shares were previous bought at was EUR 127.068. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 6,110 compared to the previous valuation of BioMerieux |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 61.99 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 61.99. The average price that BMY shares were previous bought at was USD 48.6815. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 900,817 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 76.27 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 76.27. The average price that BSX shares were previous bought at was USD 98.4451. The current market price is -22.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 619,102 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 76.27 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 76.27. The average price that BSX shares were previous bought at was USD 98.4451. The current market price is -22.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 619,102 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 226.32 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 226.32. The average price that CAH shares were previous bought at was USD 181.757. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 427,364 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 292.05 | USD 0 | The current share valuation price of CI based on adjusted close was USD 292.05. The average price that CI shares were previous bought at was USD 284.35. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in CI has increased by USD 884,453 compared to the previous valuation of Cigna Corp however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.46 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.46. The average price that CNC shares were previous bought at was USD 39.7853. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in CNC has fallen by USD 478,454 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 175.282 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 175.282. The average price that COH.AX shares were previous bought at was AUD 181.315. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 297,556 compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 78.1021 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 78.1021. The average price that COLO-B.CO shares were previous bought at was DKK 89.5825. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 398,052 compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 82.1 | USD 0 | The current share valuation price of COO based on adjusted close was USD 82.1. The average price that COO shares were previous bought at was USD 76.8475. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in COO has increased by USD 32,282 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 359.25 | USD 0 | The current share valuation price of COR based on adjusted close was USD 359.25. The average price that COR shares were previous bought at was USD 330.466. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in COR has fallen by USD 187,441 compared to the previous valuation of Cencora Inc. |
| CSL.AX - | HOLD | 0 @ AUD 126.467 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 126.467. The average price that CSL.AX shares were previous bought at was AUD 119.603. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 107,469 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 78.35 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 78.35. The average price that CVS shares were previous bought at was USD 72.8444. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 260,776 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 29.6582 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 29.6582. The average price that DEMANT.CO shares were previous bought at was DKK 35.0526. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 236,941 compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 190.71 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 190.71. The average price that DGX shares were previous bought at was USD 180.242. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 15,560 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 216.61 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 216.61. The average price that DHR shares were previous bought at was USD 213.929. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 375,279 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 216.61 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 216.61. The average price that DHR shares were previous bought at was USD 213.929. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 375,279 compared to the previous valuation of Danaher Corporation |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 210.269 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 210.269. The average price that DIM.PA shares were previous bought at was EUR 228.27. The current market price is -7.9% lower than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 17,669 compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 69.97 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 69.97. The average price that DXCM shares were previous bought at was USD 68.9354. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in DXCM has fallen by USD 35,505 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 301.515 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 301.515. The average price that EL.PA shares were previous bought at was EUR 339.054. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 32,103 compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 338.98 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 338.98. The average price that ELV shares were previous bought at was USD 343.941. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 116,942 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 338.98 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 338.98. The average price that ELV shares were previous bought at was USD 343.941. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 116,942 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 80.3726 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 80.3726. The average price that ERF.PA shares were previous bought at was EUR 71.6347. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 2,872 compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 78.71 | USD 0 | The current share valuation price of EW based on adjusted close was USD 78.71. The average price that EW shares were previous bought at was USD 81.586. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in EW has fallen by USD 445,583 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 48.0344 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 48.0344. The average price that FME.DE shares were previous bought at was EUR 48.714. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 20,785 compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 24.0018 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 24.0018. The average price that FPH.NZ shares were previous bought at was NZD 21.5706. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in FPH.NZ has increased by NZD 11,729 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 58.8138 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 58.8138. The average price that FRE.DE shares were previous bought at was EUR 54.0691. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 25,278 compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 189.229 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 189.229. The average price that GALD.SW shares were previous bought at was CHF 188.255. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 12,449 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 80.65 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 80.65. The average price that GEHC shares were previous bought at was USD 79.0142. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 6,231 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 152.5 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 152.5. The average price that GILD shares were previous bought at was USD 119.488. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 1,657,677 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 309.876 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 309.876. The average price that GMAB.CO shares were previous bought at was DKK 296.475. The current market price is 4.5% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 305,931 compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.8478 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.8478. The average price that GRF.MC shares were previous bought at was EUR 12.988. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 1,810 compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 29.9236 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 29.9236. The average price that GSK.L shares were previous bought at was GBP 23.5379. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 921,721 compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 501.69 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 501.69. The average price that HCA shares were previous bought at was USD 455.867. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 22,676 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.9656 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.9656. The average price that HIK.L shares were previous bought at was GBP 22.2686. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 2,871 compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 5.41973 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 5.41973. The average price that HLN.L shares were previous bought at was GBP 4.91084. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 74,386 compared to the previous valuation of Haleon PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.81 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.81. The average price that HOLX shares were previous bought at was USD 72.0253. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 6,453 compared to the previous valuation of Hologic Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 193.94 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 193.94. The average price that HUM shares were previous bought at was USD 265.131. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 139,424 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 193.94 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 193.94. The average price that HUM shares were previous bought at was USD 265.131. The current market price is -26.9% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 139,424 compared to the previous valuation of Humana Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 644.61 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 644.61. The average price that IDXX shares were previous bought at was USD 649.213. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in IDXX has increased by USD 89,759 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 119.72 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 119.72. The average price that ILMN shares were previous bought at was USD 119.733. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in ILMN has fallen by USD 82,364 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 108.39 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 108.39. The average price that INCY shares were previous bought at was USD 103.133. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 83,821 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 149.86 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 149.86. The average price that INSM shares were previous bought at was USD 182.2. The current market price is -17.7% lower than average price they were purchased at. The value of the holding in INSM has fallen by USD 55,360 compared to the previous valuation of Insmed Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 160.863 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 160.863. The average price that IPN.PA shares were previous bought at was EUR 138.353. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 2,945 compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 187.49 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 187.49. The average price that IQV shares were previous bought at was USD 209.611. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in IQV has fallen by USD 2,132,544 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 488.15 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 488.15. The average price that ISRG shares were previous bought at was USD 542.778. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in ISRG has fallen by USD 247,979 compared to the previous valuation of Intuitive Surgical Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 239.99 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 239.99. The average price that JNJ shares were previous bought at was USD 177.042. The current market price is 35.6% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 1,656,473 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 277.2 | USD 0 | The current share valuation price of LH based on adjusted close was USD 277.2. The average price that LH shares were previous bought at was USD 260.743. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in LH has increased by USD 14,366 compared to the previous valuation of Laboratory Corporation of America Holdings however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1058.18 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1058.18. The average price that LLY shares were previous bought at was USD 918.719. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in LLY has increased by USD 1,095,240 compared to the previous valuation of Eli Lilly and Company however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| LONN.SW - | HOLD | 0 @ CHF 667.14 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 667.14. The average price that LONN.SW shares were previous bought at was CHF 676.718. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in LONN.SW has fallen by CHF 18,640 compared to the previous valuation of |
| MCK - McKesson Corporation | HOLD | 0 @ USD 948.68 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 948.68. The average price that MCK shares were previous bought at was USD 797.826. The current market price is 18.9% higher than average price they were purchased at. The value of the holding in MCK has increased by USD 1,885,240 compared to the previous valuation of McKesson Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 102.9 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 102.9. The average price that MDT shares were previous bought at was USD 97.5886. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 7,654 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 121.93 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 121.93. The average price that MRK shares were previous bought at was USD 87.9772. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 1,768,428 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 121.93 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 121.93. The average price that MRK shares were previous bought at was USD 87.9772. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 1,768,428 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 143.548 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 143.548. The average price that MRK.DE shares were previous bought at was EUR 137.019. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 17,151 compared to the previous valuation of Merck KGaA |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1373.57 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1373.57. The average price that MTD shares were previous bought at was USD 1455.71. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 33,218 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1373.57 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1373.57. The average price that MTD shares were previous bought at was USD 1455.71. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 33,218 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.2 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.2. The average price that NBIX shares were previous bought at was USD 142.165. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in NBIX has increased by USD 8,182 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 46.7663 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 46.7663. The average price that NOVO-B.CO shares were previous bought at was DKK 54.4696. The current market price is -14.1% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 4,261,050 compared to the previous valuation of Novo Nordisk A/S |
| NTRA - Natera Inc | HOLD | 0 @ USD 203.04 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 203.04. The average price that NTRA shares were previous bought at was USD 194.07. The current market price is 4.6% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 105,056 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 87.287 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 87.287. The average price that ORNBV.HE shares were previous bought at was EUR 70.47. The current market price is 23.9% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 20,563 compared to the previous valuation of Orion Oyj however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 27.22 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 27.22. The average price that PFE shares were previous bought at was USD 24.9116. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 169,220 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 29.3006 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 29.3006. The average price that PHIA.AS shares were previous bought at was EUR 27.0173. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 11,411 compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 110.436 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 110.436. The average price that PME.AX shares were previous bought at was AUD 164.271. The current market price is -32.8% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 24,283 compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 241.93 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 241.93. The average price that PODD shares were previous bought at was USD 322.758. The current market price is -25.0% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 52,531 compared to the previous valuation of Insulet Corporation |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 55.788 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 55.788. The average price that REC.MI shares were previous bought at was EUR 57.7774. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 3,657 compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 785.51 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 785.51. The average price that REGN shares were previous bought at was USD 722.712. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 245,780 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 271.63 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 271.63. The average price that RMD shares were previous bought at was USD 253.496. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in RMD has increased by USD 82,947 compared to the previous valuation of ResMed Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 470.558 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 470.558. The average price that RO.SW shares were previous bought at was CHF 355.54. The current market price is 32.4% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 86,688 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 459.723 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 459.723. The average price that ROG.SW shares were previous bought at was CHF 370.477. The current market price is 24.1% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 333,421 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 44.65 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 44.65. The average price that RPRX shares were previous bought at was USD 37.9968. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 23,158 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 94.9815 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 94.9815. The average price that SAN.PA shares were previous bought at was EUR 98.2932. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 7,452 compared to the previous valuation of Sanofi SA however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 79.2002 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 79.2002. The average price that SDZ.SW shares were previous bought at was CHF 63.8739. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 8,481 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.4283 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.4283. The average price that SHL.AX shares were previous bought at was AUD 15.1239. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 9,932 compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 48.9328 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 48.9328. The average price that SHL.DE shares were previous bought at was EUR 53.0462. The current market price is -7.8% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 8,578 compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 2.19303 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 2.19303. The average price that SIG.AX shares were previous bought at was AUD 1.90932. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in SIG.AX has increased by AUD 37,377 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 17.2489 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 17.2489. The average price that SN.L shares were previous bought at was GBP 16.891. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in SN.L has increased by GBP 4,399 compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 43.8769 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 43.8769. The average price that SOBI.ST shares were previous bought at was SEK 33.7135. The current market price is 30.1% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 79,289 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 78.12 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 78.12. The average price that SOLV shares were previous bought at was USD 75.621. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in SOLV has increased by USD 5,705 compared to the previous valuation of Solventum Corp. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SOON.SW - | HOLD | 0 @ CHF 265.463 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 265.463. The average price that SOON.SW shares were previous bought at was CHF 269.34. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 49,536 compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 283.195 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 283.195. The average price that SRT3.DE shares were previous bought at was EUR 269.167. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 50,092 compared to the previous valuation of Sartorius AG however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 252.16 | USD 0 | The current share valuation price of STE based on adjusted close was USD 252.16. The average price that STE shares were previous bought at was USD 248.371. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in STE has fallen by USD 472,860 compared to the previous valuation of STERIS plc |
| STMN.SW - | HOLD | 0 @ CHF 128.475 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 128.475. The average price that STMN.SW shares were previous bought at was CHF 121.166. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in STMN.SW has increased by CHF 72,063 compared to the previous valuation of however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| SYK - Stryker Corporation | HOLD | 0 @ USD 358.29 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 358.29. The average price that SYK shares were previous bought at was USD 366.946. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 185,052 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 34.69 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 34.69. The average price that TEVA shares were previous bought at was USD 23.4264. The current market price is 48.1% higher than average price they were purchased at. The value of the holding in TEVA has fallen by USD 23,360 compared to the previous valuation of Teva Pharma Industries Ltd ADR |
| TMO - Time Out Group plc | HOLD | 0 @ USD 542.83 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 542.83. The average price that TMO shares were previous bought at was USD 500.452. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 1,001,030 compared to the previous valuation of Time Out Group plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 309.671 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 309.671. The average price that UCB.BR shares were previous bought at was EUR 265.271. The current market price is 16.7% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 60,555 compared to the previous valuation of UCB SA however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 276.65 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 276.65. The average price that UNH shares were previous bought at was USD 324.259. The current market price is -14.7% lower than average price they were purchased at. The value of the holding in UNH has fallen by USD 727,269 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 485.36 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 485.36. The average price that UTHR shares were previous bought at was USD 454.69. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 11,355 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 183.65 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 183.65. The average price that VEEV shares were previous bought at was USD 256.643. The current market price is -28.4% lower than average price they were purchased at. The value of the holding in VEEV has fallen by USD 648,583 compared to the previous valuation of Veeva Systems Inc Class A |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 477.92 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 477.92. The average price that VRTX shares were previous bought at was USD 437.561. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 217,672 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 381.29 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 381.29. The average price that WAT shares were previous bought at was USD 358.742. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 37,115 compared to the previous valuation of Waters Corporation however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 381.29 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 381.29. The average price that WAT shares were previous bought at was USD 358.742. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in WAT has increased by USD 37,115 compared to the previous valuation of MULETFWATIMETFP however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 248.95 | USD 0 | The current share valuation price of WST based on adjusted close was USD 248.95. The average price that WST shares were previous bought at was USD 266.969. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in WST has increased by USD 21,068 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 89.91 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 89.91. The average price that ZBH shares were previous bought at was USD 94.1018. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 19,114 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 127.42 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 127.42. The average price that ZTS shares were previous bought at was USD 132.244. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in ZTS has increased by USD 256,013 compared to the previous valuation of Zoetis Inc however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |